Track topics on Twitter Track topics that are important to you
Two rivals in the emerging Duchenne muscular dystrophy (DMD) therapy area have experienced contrasting fortunes this week. Yesterday saw Sarepta increase its forecast for its full year revenues, up to between $150 and $155 million, thanks to bette...
Original Article: Contrasting fortunes for Duchenne rivals, as PTC fails and Sarepta soarsNEXT ARTICLE
Muscular dystrophy is a group of degenerative inherited disorders causing muscle weakness and loss of muscle tissue. The different types are Becker muscular dystrophy, Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Facioscapulohumeral mu...